These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 36814327)
1. Preliminary outcomes of DEB-TACE loaded with raltitrexed in the treatment of unresectable or recurrent hepatocellular carcinoma. Bi Y; Wang Y; Zhang W; Lu H; Ren J; Han X Cancer Imaging; 2023 Feb; 23(1):19. PubMed ID: 36814327 [TBL] [Abstract][Full Text] [Related]
2. Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma. Bi Y; Jiao D; Ren J; Han X Can J Gastroenterol Hepatol; 2022; 2022():2602121. PubMed ID: 36051250 [TBL] [Abstract][Full Text] [Related]
3. Oxaliplatin Eluting CalliSpheres Microspheres for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma. Bi Y; Ren K; Ren J; Ma J; Han X Front Pharmacol; 2022; 13():923585. PubMed ID: 36034827 [No Abstract] [Full Text] [Related]
4. Efficacy and safety of raltitrexed-eluting CalliSpheres Sun Z; Jiao D; Fang Y; Liu Y; Xu K; Zhang C; Huang Y; Han X Ther Adv Med Oncol; 2024; 16():17588359241229661. PubMed ID: 38362379 [TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes of doxorubicin-eluting CalliSpheres® beads-transarterial chemoembolization for unresectable or recurrent esophageal carcinoma. Bi Y; Shi X; Ren J; Yi M; Han X; Song M BMC Gastroenterol; 2021 May; 21(1):231. PubMed ID: 34020608 [TBL] [Abstract][Full Text] [Related]
6. Preliminary outcomes of raltitrexed eluting bead-transarterial chemoembolization using Callispheres® beads for gastrointestinal adenocarcinoma liver metastasis. Bi Y; Jiao D; Wang Y; Han X; Ren J World J Surg Oncol; 2022 Jul; 20(1):229. PubMed ID: 35821043 [TBL] [Abstract][Full Text] [Related]
7. Transarterial chemoembolization of unresectable renal cell carcinoma with doxorubicin-loaded CalliSpheres drug-eluting beads. Bi Y; Shi X; Ren J; Yi M; Han X Sci Rep; 2022 May; 12(1):8136. PubMed ID: 35581365 [TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of oxaliplatin-loaded drug-eluting callispheres beads transarterial chemoembolization for unresectable or recurrent esophageal carcinoma. Bi Y; Ren J; Han X World J Surg Oncol; 2024 Oct; 22(1):272. PubMed ID: 39390475 [TBL] [Abstract][Full Text] [Related]
9. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study. Wu B; Zhou J; Ling G; Zhu D; Long Q World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773 [TBL] [Abstract][Full Text] [Related]
10. Short-term efficacy and safety of callispheres drug-loaded microsphere embolization in primary hepatocellular carcinoma. Li J; Wang N; Shi C; Liu Q; Song J; Ye X J Cancer Res Ther; 2021 Jul; 17(3):733-739. PubMed ID: 34269307 [TBL] [Abstract][Full Text] [Related]
11. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma. Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378 [TBL] [Abstract][Full Text] [Related]
12. Conventional versus Doxorubicin-Eluting Beads Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: a Tertiary Medical Centre Experience in Malaysia. Rahman FA; Naidu J; Ngiu CS; Yaakob Y; Mohamed Z; Othman H; Jarmin R; Elias MH; Hamid NA; Mokhtar NM; Ali RR Asian Pac J Cancer Prev; 2016; 17(8):4037-41. PubMed ID: 27644658 [TBL] [Abstract][Full Text] [Related]
13. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting. Karalli A; Teiler J; Haji M; Seth E; Brismar TB; Wahlin S; Axelsson R; Stål P Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338 [No Abstract] [Full Text] [Related]
14. Safety, efficacy, and survival of different transarterial chemoembolization techniques in the management of unresectable hepatocellular carcinoma: a comparative single-center analysis. Schindler P; Kaldewey D; Rennebaum F; Trebicka J; Pascher A; Wildgruber M; Köhler M; Masthoff M J Cancer Res Clin Oncol; 2024 May; 150(5):235. PubMed ID: 38710956 [TBL] [Abstract][Full Text] [Related]
15. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC. Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737 [TBL] [Abstract][Full Text] [Related]
16. Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: A single-center propensity score matching analysis. Shi Q; Liu J; Li T; Zhou C; Wang Y; Huang S; Yang C; Chen Y; Xiong B Clin Res Hepatol Gastroenterol; 2022 May; 46(5):101893. PubMed ID: 35247625 [TBL] [Abstract][Full Text] [Related]
17. Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Reyes DK; Vossen JA; Kamel IR; Azad NS; Wahlin TA; Torbenson MS; Choti MA; Geschwind JF Cancer J; 2009; 15(6):526-32. PubMed ID: 20010173 [TBL] [Abstract][Full Text] [Related]
18. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752 [TBL] [Abstract][Full Text] [Related]
19. Comparative Study of the Short-Term Efficacy and Safety between DEB-TACE and C-TACE in the Treatment of Unresectable Hepatocellular Carcinoma, a Retrospective Study. Hai L; Liu S; Ma L; Ding X; Bai X; Luo X Technol Cancer Res Treat; 2024; 23():15330338241250315. PubMed ID: 38773767 [No Abstract] [Full Text] [Related]
20. Comparison of CalliSpheres Shi Z; Wang D; Kang T; Yi R; Cui L; Jiang H Radiol Oncol; 2023 Mar; 57(1):70-79. PubMed ID: 36794998 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]